PREPOPIK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREPOPIK (PREPOPIK).
PREPOPIK is a combination of picosulfate, a stimulant laxative that acts locally on the colonic mucosa to increase peristalsis and water secretion, and magnesium oxide and citric acid, which form magnesium citrate, an osmotic laxative that draws water into the colon. The dual action leads to bowel evacuation.
| Metabolism | Picosulfate is hydrolyzed by intestinal bacteria to its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM). Magnesium citrate is not metabolized and is excreted renally. |
| Excretion | Primarily fecal (unabsorbed drug) with minimal renal excretion (<1%). |
| Half-life | Not applicable as systemic absorption is negligible; local effect in colon. |
| Protein binding | Negligible due to limited systemic absorption. |
| Volume of Distribution | Not applicable; minimal systemic distribution. |
| Bioavailability | Negligible (<1%) due to local colonic action. |
| Onset of Action | Oral: bowel movement typically within 1-4 hours. |
| Duration of Action | Up to 24 hours for complete bowel evacuation. |
One sachet containing sodium picosulfate 10 mg and magnesium oxide 3.5 g and citric acid 12 g, reconstituted in water, taken as a split dose: first dose in the evening before colonoscopy, second dose the next morning, each followed by at least 5 glasses (250 mL) of clear liquids.
| Dosage form | FOR SOLUTION |
| Renal impairment | Contraindicated in patients with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m². For eGFR 30–60 mL/min/1.73 m², use with caution and ensure adequate hydration; no dose adjustment recommended. |
| Liver impairment | No specific dose adjustment for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh class C) due to potential for electrolyte disturbances. |
| Pediatric use | Not established; safety and efficacy in pediatric patients (<18 years) have not been studied. |
| Geriatric use | No specific dose adjustment; monitor renal function and hydration status closely due to increased risk of electrolyte abnormalities and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREPOPIK (PREPOPIK).
| Breastfeeding | No data on excretion in human milk. M/P ratio unknown. However, low systemic absorption suggests minimal excretion. Use with caution in breastfeeding mothers, especially if infant has electrolyte disturbances. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at exposures up to 1.6 times the human therapeutic dose. However, due to the laxative effect and potential for electrolyte disturbances, caution is advised. First trimester: theoretical risk of dehydration; second and third trimesters: may precipitate electrolyte imbalances affecting fetal homeostasis. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Gastric retention","Bowel obstruction or perforation","Toxic colitis or megacolon","Severe inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease)","Hypersensitivity to any component","Severe renal impairment (CrCl < 30 mL/min)"]
| Precautions | ["Risk of fluid and electrolyte abnormalities, including dehydration, hypokalemia, and hypermagnesemia.","Use with caution in patients with renal impairment, history of seizures, or those taking medications that lower seizure threshold.","Avoid use in patients with bowel obstruction, perforation, or severe inflammatory bowel disease.","Prolonged QT interval may occur with electrolyte imbalances."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, potassium, calcium, magnesium) and fluid balance during prolonged use. Assess fetal well-being via ultrasound if used long-term. Avoid use in preeclampsia or compromised renal function. |
| Fertility Effects | No adverse effects on fertility observed in animal studies. Theoretical risk of electrolyte disturbances affecting ovulation, but no clinical evidence. |